Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
NCT04510636Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Dec 2021
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, bendamustine in Hodgkin lymphoma (HL), sponsored by University Health Network. Started Dec 2021; status: recruiting.
02
Drugs
pembrolizumabbendamustine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04510636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510636.